Nucgnex Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 24-12-2024
- Paid Up Capital ₹ 1.83 M
as on 24-12-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 M
as on 24-12-2024
- Revenue 144.06%
(FY 2022)
- Profit 112.62%
(FY 2022)
- Ebitda 115.98%
(FY 2022)
- Net Worth 97.55%
(FY 2022)
- Total Assets 55.71%
(FY 2022)
About Nucgnex Lifesciences
The Corporate was formerly known as Nucgn Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.83 M.
The company currently has active open charges totaling ₹6.00 M.
Archana Gandhi, Sameer Gandhi, and Pious Gandhi serve as directors at the Company.
- CIN/LLPIN
U24110PN2017PTC170493
- Company No.
170493
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nucgnex Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Archana Gandhi  | Director | 18-May-2017 | Current |
| Sameer Gandhi | Director | 18-May-2017 | Current |
| Pious Gandhi | Director | 01-Oct-2019 | Current |
Financial Performance of Nucgnex Lifesciences.
Nucgnex Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 144.06% increase. The company also saw a substantial improvement in profitability, with a 112.62% increase in profit. The company's net worth Soared by an impressive increase of 97.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucgnex Lifesciences?
In 2022, Nucgnex Lifesciences had a public holding of 11.43%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Dec 2022 | ₹6.00 M | Open |
How Many Employees Work at Nucgnex Lifesciences?
Nucgnex Lifesciences has a workforce of 47 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucgnex Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucgnex Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
